160 related articles for article (PubMed ID: 29735547)
21. Histone hypoacetylation contributes to CXCL12 downregulation in colon cancer: impact on tumor growth and cell migration.
Romain B; Benbrika-Nehmar R; Marisa L; Legrain M; Lobstein V; Oravecz A; Poidevin L; Bour C; Freund JN; Duluc I; Guenot D; Pencreach E
Oncotarget; 2017 Jun; 8(24):38351-38366. PubMed ID: 28418886
[TBL] [Abstract][Full Text] [Related]
22. Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression.
Baglio SR; Lagerweij T; Pérez-Lanzón M; Ho XD; Léveillé N; Melo SA; Cleton-Jansen AM; Jordanova ES; Roncuzzi L; Greco M; van Eijndhoven MAJ; Grisendi G; Dominici M; Bonafede R; Lougheed SM; de Gruijl TD; Zini N; Cervo S; Steffan A; Canzonieri V; Martson A; Maasalu K; Köks S; Wurdinger T; Baldini N; Pegtel DM
Clin Cancer Res; 2017 Jul; 23(14):3721-3733. PubMed ID: 28053020
[No Abstract] [Full Text] [Related]
23. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway.
Zhao S; Wang J; Qin C
J Exp Clin Cancer Res; 2014 Dec; 33(1):103. PubMed ID: 25471741
[TBL] [Abstract][Full Text] [Related]
24. Stem cell autocrine CXCL12/CXCR4 stimulates invasion and metastasis of esophageal cancer.
Wang X; Cao Y; Zhang S; Chen Z; Fan L; Shen X; Zhou S; Chen D
Oncotarget; 2017 May; 8(22):36149-36160. PubMed ID: 28193907
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
26. A novel interplay between HOTAIR and DNA methylation in osteosarcoma cells indicates a new therapeutic strategy.
Li X; Lu H; Fan G; He M; Sun Y; Xu K; Shi F
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2189-2200. PubMed ID: 28730284
[TBL] [Abstract][Full Text] [Related]
27. Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling.
Foley JM; Scholten DJ; Monks NR; Cherba D; Monsma DJ; Davidson P; Dylewski D; Dykema K; Winn ME; Steensma MR
J Transl Med; 2015 Apr; 13():110. PubMed ID: 25889105
[TBL] [Abstract][Full Text] [Related]
28. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
[TBL] [Abstract][Full Text] [Related]
29. Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer.
Yang DL; Xin MM; Wang JS; Xu HY; Huo Q; Tang ZR; Wang HF
Genet Mol Res; 2015 Dec; 14(4):17699-707. PubMed ID: 26782415
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas.
Yang SF; Lee WJ; Tan P; Tang CH; Hsiao M; Hsieh FK; Chien MH
Oncotarget; 2015 Feb; 6(5):2736-53. PubMed ID: 25605016
[TBL] [Abstract][Full Text] [Related]
31. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
Sorrentino C; Miele L; Porta A; Pinto A; Morello S
Oncotarget; 2016 Sep; 7(39):64274-64288. PubMed ID: 27590504
[TBL] [Abstract][Full Text] [Related]
32. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway.
Wang C; Zhou X; Li W; Li M; Tu T; Ba X; Wu Y; Huang Z; Fan G; Zhou G; Wu S; Zhao J; Zhang J; Chen J
Cancer Lett; 2017 Sep; 403():271-279. PubMed ID: 28642171
[TBL] [Abstract][Full Text] [Related]
33. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.
Phillips RJ; Burdick MD; Lutz M; Belperio JA; Keane MP; Strieter RM
Am J Respir Crit Care Med; 2003 Jun; 167(12):1676-86. PubMed ID: 12626353
[TBL] [Abstract][Full Text] [Related]
34. CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p.
Yu X; Wang D; Wang X; Sun S; Zhang Y; Wang S; Miao R; Xu X; Qu X
J Exp Clin Cancer Res; 2019 Jan; 38(1):32. PubMed ID: 30678736
[TBL] [Abstract][Full Text] [Related]
35. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
36. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
37. Tumor-Associated Macrophages Promote Epigenetic Silencing of Gelsolin through DNA Methyltransferase 1 in Gastric Cancer Cells.
Wang HC; Chen CW; Yang CL; Tsai IM; Hou YC; Chen CJ; Shan YS
Cancer Immunol Res; 2017 Oct; 5(10):885-897. PubMed ID: 28835422
[TBL] [Abstract][Full Text] [Related]
38. Coexpression of CXCR4 and MMP9 predicts lung metastasis and poor prognosis in resected osteosarcoma.
Ren Z; Liang S; Yang J; Han X; Shan L; Wang B; Mu T; Zhang Y; Yang X; Xiong S; Wang G
Tumour Biol; 2016 Apr; 37(4):5089-96. PubMed ID: 26546437
[TBL] [Abstract][Full Text] [Related]
39. Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model.
Qin G; Chen Y; Li H; Xu S; Li Y; Sun J; Rao W; Chen C; Du M; He K; Ye Y
Mol Med Rep; 2016 Jul; 14(1):57-68. PubMed ID: 27177128
[TBL] [Abstract][Full Text] [Related]
40. Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: an accelerated growth factor in glioblastomas.
Komatani H; Sugita Y; Arakawa F; Ohshima K; Shigemori M
Int J Oncol; 2009 Mar; 34(3):665-72. PubMed ID: 19212671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
